[SCHEDULE 13G/A] Dianthus Therapeutics, Inc. /DE/ Amended Passive Investment Disclosure
Point72 reports 6.9% stake in Dianthus Therapeutics
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen report beneficial ownership of 2,981,674 shares of Dianthus Therapeutics common stock, representing 6.9% of the outstanding class as of the close of business on February 13, 2026.
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Point72 Asset Management, Point72 Capital Advisors, and Steven A. Cohen report beneficial ownership of 2,981,674 shares of Dianthus Therapeutics common stock, representing 6.9% of the outstanding class as of the close of business on February 13, 2026.
The shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management, with shared voting and dispositive power reported for each filing person. As of December 31, 2025, they had reported beneficial ownership of 1,166,088 shares, or 2.7% of the class. They certify the position is held on a passive basis and not for the purpose of changing or influencing control of Dianthus Therapeutics.
Insights
Point72 discloses a 6.9% passive stake in Dianthus.
Point72 Asset Management, its affiliate and Steven A. Cohen collectively report beneficial ownership of 2,981,674 Dianthus Therapeutics shares, equal to 6.9% of the common stock as of February 13, 2026. The shares are held through Point72 Associates, LLC, with Point72 retaining investment and voting power via an investment management agreement.
The filing shows growth from 1,166,088 shares, or 2.7%, as of December 31, 2025, indicating a notable increase in institutional exposure over a short period. However, they expressly certify the position is not intended to change or influence control of Dianthus, consistent with a passive Schedule 13G filing rather than an activist stance.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake does Point72 report in Dianthus Therapeutics (DNTH)?
Point72-related entities report beneficial ownership of 2,981,674 Dianthus Therapeutics shares, representing 6.9% of the outstanding common stock as of February 13, 2026. This stake is held through Point72 Associates, LLC, with shared voting and dispositive power reported by the filers.
Which entities are reporting beneficial ownership of Dianthus Therapeutics (DNTH)?
The filing lists Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as reporting persons. The shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management, with Cubist Systematic Strategies, LLC acting as a sub-advisor.
How has Point72’s position in Dianthus Therapeutics (DNTH) changed over time?
As of December 31, 2025, the reporting persons may have been deemed to beneficially own 1,166,088 shares, or 2.7% of the class. By February 13, 2026, reported beneficial ownership increased to 2,981,674 shares, or 6.9% of the outstanding common stock.
Is Point72’s Dianthus Therapeutics (DNTH) stake intended to influence control of the company?
No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of Dianthus Therapeutics. The position is reported on Schedule 13G, which is used for passive ownership rather than activist control efforts.
Who has the right to dividends and sale proceeds from Dianthus Therapeutics (DNTH) shares?
The filing notes that Point72 Associates, LLC has the right to receive, or direct the receipt of, dividends and proceeds from the sale of more than 5% of the outstanding Dianthus common shares, reflecting its role as the fund that directly holds the securities.
What voting and dispositive powers are reported over Dianthus Therapeutics (DNTH) shares?
Each reporting person shows zero sole voting and dispositive power and 2,981,674 shares of shared voting and shared dispositive power. Point72 Asset Management maintains investment and voting power pursuant to an investment management agreement with Point72 Associates.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Dianthus Therapeutics, Inc. /DE/
(Name of Issuer)
Common Stock, par value $0.001 per share
(Title of Class of Securities)
252828108
(CUSIP Number)
12/31/2025
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
SCHEDULE 13G
CUSIP No.
252828108
1
Names of Reporting Persons
Point72 Asset Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,981,674.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,981,674.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,981,674.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.9 %
12
Type of Reporting Person (See Instructions)
PN
Comment for Type of Reporting Person: The information set forth on this cover page reflects information as of the close of business on February 13, 2026. As of December 31, 2025, the Reporting Person may have been deemed to beneficially own 1,166,088 Shares (as defined in Item 2(a)), representing 2.7% of the Shares outstanding as of such time.
SCHEDULE 13G
CUSIP No.
252828108
1
Names of Reporting Persons
Point72 Capital Advisors, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,981,674.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,981,674.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,981,674.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.9 %
12
Type of Reporting Person (See Instructions)
CO
Comment for Type of Reporting Person: The information set forth on this cover page reflects information as of the close of business on February 13, 2026. As of December 31, 2025, the Reporting Person may have been deemed to beneficially own 1,166,088 Shares, representing 2.7% of the Shares outstanding as of such time.
SCHEDULE 13G
CUSIP No.
252828108
1
Names of Reporting Persons
Steven A. Cohen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
2,981,674.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
2,981,674.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,981,674.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.9 %
12
Type of Reporting Person (See Instructions)
IN
Comment for Type of Reporting Person: The information set forth on this cover page reflects information as of the close of business on February 13, 2026. As of December 31, 2025, the Reporting Person may have been deemed to beneficially own 1,166,088 Shares, representing 2.7% of the Shares outstanding as of such time.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Dianthus Therapeutics, Inc. /DE/
(b)
Address of issuer's principal executive offices:
7 Times Square, 43rd Floor, New York, NY 10036
Item 2.
(a)
Name of person filing:
This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.001 per share ("Shares"), of Dianthus Therapeutics, Inc. held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the Shares held by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
Cubist Systematic Strategies, LLC is a relying adviser on the Form ADV of Point72 Asset Management and acts as a sub-advisor with respect to a portion of the Shares reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)
Citizenship:
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.001 per share
(e)
CUSIP No.:
252828108
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 13, 2026. Such information as of December 31, 2025 is set forth in the footnote on such cover page.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein.
(b)
Percent of class:
6.9%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 13, 2026.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 13, 2026.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 13, 2026.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on February 13, 2026.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
